Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02168725 · ClinicalTrials.gov registry record · Phase 1
Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors
A Phase 1 study, sponsored by Traws Pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT02168725 is a Phase 1 study that was terminated before completion, run by Traws Pharma. The registered enrollment target is 26 participants.
The verdict
NCT02168725, a Phase 1 study, was terminated before completion, sponsored by Traws Pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The main objectives of this study are to determine the safety profile of briciclib, an experimental anti-cancer drug, as it is administered intravenously once weekly as escalating doses in adult patients with advanced cancer and solid tumors, and to determine the highest dose of briciclib that can be safely given. Secondary objectives are to determine how the amount of briciclib in circulation changes over time and how much briciclib gets into the urine for excretion, and to document potential anti-tumor effects of briciclib.
Interventions
- DRUG briciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02168725
The ClinicalTrials.gov registry entry for NCT02168725 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Traws Pharma, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which briciclib is the first listed.
NCT02168725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02168725 about?
NCT02168725 is a clinical study titled "Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors". The main objectives of this study are to determine the safety profile of briciclib, an experimental anti-cancer drug, as it is administered intravenously once weekly as escalating doses in adult patients with advanced cancer and solid tumors, and to determine the highest dose of briciclib that can b...
What is the current status of trial NCT02168725?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2014-06. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02168725?
The interventions under investigation include: briciclib (DRUG).
Who is sponsoring clinical trial NCT02168725?
This trial is sponsored by Traws Pharma, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.